Bicara Therapeutics (BCAX) Insider Trading & Ownership $15.26 +0.55 (+3.74%) As of 12:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Bicara Therapeutics (NASDAQ:BCAX) Insider Buying and Selling ActivityNumber OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$34.25 MNumber OfInsiders Selling(Last 12 Months)0 Get BCAX Insider Trade Alerts Want to know when executives and insiders are buying or selling Bicara Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BCAX Insider Buying and Selling by Quarter Bicara Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/17/2024James E FlynnMajor ShareholderBuy70,000$18.00$1,260,000.00 9/16/2024Ra Capital Management, L.P.DirectorBuy1,833,000$18.00$32,994,000.00 (Data available from 1/1/2013 forward) BCAX Insider Trading Activity - Frequently Asked Questions Who is on Bicara Therapeutics's Insider Roster? The list of insiders at Bicara Therapeutics includes James E Flynn, and Ra Capital Management, L.P.. Learn more on insiders at BCAX. Which Bicara Therapeutics insiders have been buying company stock? The following insiders have purchased BCAX shares in the last 24 months: James E Flynn ($1,260,000.00), and Ra Capital Management, L.P. ($32,994,000.00). How much insider buying is happening at Bicara Therapeutics? Insiders have purchased a total of 1,903,000 BCAX shares in the last 24 months for a total of $34,254,000.00 bought. Bicara Therapeutics Key ExecutivesMs. Claire Mazumdar Clemon M.B.A. (Age 35)Ph.D., CEO & Director Compensation: $650kMr. Ryan Cohlhepp Pharm.D. (Age 48)President, COO & Director Compensation: $660kMr. Ivan Hyep M.B.A. (Age 40)Chief Financial Officer Compensation: $597.5kMs. Lara S. Meisner J.D. (Age 52)Chief Legal Officer & Corporate Secretary Ms. Rachel SalazarSVP of R&D Strategy and OperationsMs. Sathish Hasige Ph.D.Senior VP and Head of Technical Operations & Supply ChainDr. David Raben M.D. (Age 61)Chief Medical Officer Ms. Angela WindtVP & Head of Regulatory AffairsDr. Jeltje Schulten M.B.A.M.D., Senior Vice President of Clinical & Medical AffairsMr. Jean-Paul RodriqueSenior Vice President of Quality More Insider Trading Tools from MarketBeat Related Companies MRUS Insider Buying CRNX Insider Buying SWTX Insider Buying AKRO Insider Buying VKTX Insider Buying XENE Insider Buying CPRX Insider Buying PTGX Insider Buying IMVT Insider Buying SRRK Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles McDonald’s Insiders Sell Shares! Investors Should Do the Opposite5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why This page (NASDAQ:BCAX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCAX Stock Free BCAX Stock Alerts